neo-gambogic acid has been researched along with Osteogenic Sarcoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, Y; Huang, J; Ji, C; Li, J; Li, L; Li, X; Liu, Z; Wang, X; Yang, X; Zhou, J | 1 |
| Cai, H; Chen, X; Gu, W; Kang, J; Lei, H; Wang, W; Wu, YL; Xu, H; Yang, W; Yin, T; Zhang, X; Zhu, Q | 1 |
2 other study(ies) available for neo-gambogic acid and Osteogenic Sarcoma
| Article | Year |
|---|---|
Gambogenic acid induces cell death in human osteosarcoma through altering iron metabolism, disturbing the redox balance, and activating the P53 signaling pathway.
Topics: Adolescent; Animals; Cell Death; Cell Line, Tumor; Child; Humans; Mice; Osteosarcoma; Oxidation-Reduction; Reactive Oxygen Species; Signal Transduction; Tumor Suppressor Protein p53 | 2023 |
Targeting USP9x/SOX2 axis contributes to the anti-osteosarcoma effect of neogambogic acid.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Deubiquitinating Enzymes; Garcinia; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Mice; Osteosarcoma; Signal Transduction; SOXB1 Transcription Factors; Ubiquitin Thiolesterase; Ubiquitination; Xanthenes | 2020 |